Search Our Scientific Publications & Authors

Front Pharmacol 2019 2;10:296. Epub 2019 Apr 2.

Research Centre of Systemic Autoinflammatory Diseases, Behçet's Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Centre, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.

Anakinra (ANA) is an effective treatment choice in patients with adult onset Still's disease (AOSD). Variables affecting treatment survival include loss of efficacy or adverse events, but also the decision to discontinue treatment after long-term clinical remission. Aims of this study were: (i) to assess the drug retention rate (DRR) of ANA during a long-term follow-up looking for any difference related to the line of biologic treatment, the concomitant use of conventional disease modifying anti-rheumatic drugs (cDMARDs) and the different type of AOSD (systemic versus chronic articular); (ii) to identify predictive factors of lack of efficacy, loss of efficacy, and ANA withdrawal owing to long-term remission. Read More

Rev Prat 2019 Feb;69(2):188-194

Rhumatologie pédiatrique, hôpital Necker- Enfants malades, Paris, France.

Juvenile idiopathic arthritis. Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease in childhood. It comprises a heterogeneous group of disorders characterized by joint inflammation, extraarticular features including uveitis and, in some cases laboratory markers. Read More

Pediatr Rheumatol Online J 2019 Apr 11;17(1):15. Epub 2019 Apr 11.

Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.

Background: Although there are many reports on Juvenile Idiopathic arthritis-associated uveitis (JIA-U) from various countries, especially from Europe and North America, there are few reports from Asia. Our aim was to investigate the epidemiology, characteristics and predictors of JIA-U in Japan.

Methods: Data were retrospectively collected on 726 patients with JIA from medical records as of April 2016 at 15 medical centers specialized in pediatric rheumatic diseases. Read More

J AAPOS 2019 Apr 5. Epub 2019 Apr 5.

Vitreo-retina, Trauma and Uvea Services; Dr. Rajendra Prasad Center for Ophthalmic Sciences; All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.

Juvenile idiopathic arthritis (JIA) is a group of disorders occurring in children with arthritis of more than 6 weeks' duration. JIA may have varied systemic and ocular presentations, which can pose a diagnostic challenge. Chronic uveitis with insidious onset is the most common type of ocular presentation. Read More

Psychiatr Danub 2019 Mar;31(Suppl 1):44-49

Zagreb University Hospital Centre, Department of Ophthalmology, Kišpatićeva 12, 10000 Zagreb, Croatia,

JIA is the most common rheumatic disease of childhood and JIA-U is its most frequent and most devastating extraarticular manifestation. This form of uveitis is usually asymptomatic, chronic anterior uveitis, often accompained with complications. JIA-U is the main cause of vision loss and even blidness in childhood. Read More

Br J Ophthalmol 2019 Apr 2. Epub 2019 Apr 2.

The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute, Chongqing, P. R. China

Background: Idiopathic paediatric uveitis (IPU) and juvenile idiopathic arthritis associated uveitis (JIA-U) are the two most common entities in paediatric uveitis. This study addressed the possible association of IPU and JIA-U with genes that had been shown earlier to be associated with juvenile idiopathic arthritis.

Methods: We carried out a case-control association study involving 286 IPU, 134 JIA-U patients and 743 healthy individuals. Read More

Indian J Ophthalmol 2019 Apr;67(4):490-495

Department of Ophthalmology, Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.

Purpose: To evaluate the long-term outcomes of cataract surgery in children with uveitis.

Methods: Retrospective, noncomparative review of medical records of children (≤16 years) with uveitic cataract who had undergone cataract surgery between January 2001 and December 2014 at a tertiary care center was done. The main outcome measures were visual acuity and postoperative complications. Read More

BMC Rheumatol 2018 27;2. Epub 2018 Feb 27.

5Department of Women's and Children's, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

Background: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Children with JIA are at risk of intraocular inflammation (uveitis). In the initial stages of mild-moderate inflammation uveitis is asymptomatic. Read More

J Autoimmun 2019 Mar 15. Epub 2019 Mar 15.

Department of Ophthalmology and Ophtha-Lab at St. Franziskus-Hospital, Münster, Germany; Department of Ophthalmology, University of Duisburg-Essen, Essen, Germany.

Gene and protein expression profiles of iris biopsies, aqueous humor (AqH), and sera in patients with juvenile idiopathic arthritis-associated uveitis (JIAU) in comparison to control patients with primary open-angle glaucoma (POAG) and HLA-B27-positive acute anterior uveitis (AAU) were investigated. Via RNA Sequencing (RNA-Seq) and mass spectrometry-based protein expression analyses 136 genes and 56 proteins could be identified as being significantly differentially expressed (DE) between the JIAU and POAG group. Gene expression of different immunoglobulin (Ig) components as well as of the B cell-associated factors ID3, ID1, and EBF1 was significantly upregulated in the JIAU group as compared to POAG patients. Read More

Int J Rheum Dis 2019 Mar 18. Epub 2019 Mar 18.

Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.

Aim: The aim of the study was to assess the distribution of human leukocyte antigen (HLA)-B*27 subtypes and its correlation with disease phenotypes in children with enthesitis-related arthritis variant of juvenile idiopathic arthritis (JIA-ERA).

Method: One hundred and sixty patients (132 males, 28 females) satisfying the International League Against Rheumatism (ILAR) classification criteria for JIA-ERA were assessed and relevant demographic, clinical and radiographic data were documented. HLA-B*27 typing was done for all the patients and B*27 positive samples were subjected to high-resolution gene sequencing. Read More

Expert Rev Clin Immunol 2019 Mar 15:1-10. Epub 2019 Mar 15.

a Department of Ophthalmology, University Medical Center Utrecht , Utrecht University , Utrecht , The Netherlands.

Introduction: Uveitis is a sight-threatening eye inflammation and common manifestation of juvenile idiopathic arthritis (JIA). New biomarkers that can predict uveitis are needed to alleviate personalized clinical screening. In this review, we outline clinical and molecular risk factors for uveitis and discuss their putative biology and value for clinical practice. Read More

Curr Opin Ophthalmol 2019 May;30(3):138-150

Tennessee Retina, Nashville, USA.

Purpose Of Review: There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with ongoing evaluation for efficacy in uveitis; and therapeutics for which investigation for efficacy in NIU is warranted.

Recent Findings: The tumor necrosis factor-alpha (TNF-α) inhibitor adalimumab has recently gained approval by the Food and Drug Administration for the treatment of noninfectious intermediate, posterior, and panuveitis. Read More

Curr Opin Ophthalmol 2019 May;30(3):179-186

Department of Ophthalmology, IHU FORESIGHT, Pitié-Salpêtrière Hospital, APHP, Sorbonne-University.

Purpose Of Review: The aim of this review is to highlight recent changes in the treatment of juvenile idiopathic arthritis (JIA) - associated uveitis in the era of biologics.

Recent Findings: Early introduction of steroid-sparing therapies is paramount for appropriate management. Biologic therapies have improved the therapeutic management of JIA-uveitis and adalimumab is currently approved for pediatric-onset noninfectious chronic anterior uveitis with an inadequate response to topical steroids and methotrexate. Read More

Rheumatol Ther 2019 Mar 5. Epub 2019 Mar 5.

Oregon Health and Science University, Portland, OR, USA.

Introduction: The primary goals of treating ankylosing spondylitis (AS) patients are to maximize long-term health-related quality of life through control of symptoms and inflammation, prevention of progressive structural damage, and preservation of function. The objective of this study was to describe treatment patterns (persistence, discontinuations, and switch) in the 2 years following the initiation of tumor necrosis factor inhibitors (TNFi) therapy in AS patients.

Methods: Adult patients with ≥ 2 AS diagnostic codes (ICD-9: 720. Read More

Clin Exp Ophthalmol 2019 Mar 4. Epub 2019 Mar 4.

Department of Ophthalmology, Sydney Eye Hospital, Sydney, Australia.

Importance: Paediatric uveitis is a severe sight-threatening uveitis due to disease progression and treatment failure. Biological agents are a promising new treatment. This study provides real-world data on their use from Sydney, Australia. Read More

Lancet Child Adolesc Health 2019 Apr 26;3(4):255-263. Epub 2019 Feb 26.

Clinic of Paediatrics and Rheumatology, IRCCS Istituto Giannina Gaslini, University of Genoa, Genoa, Italy; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Sciences, University of Genoa, Genoa, Italy. Electronic address:

Background: To our knowledge, the characteristics and burden of childhood arthritis have never been studied on a worldwide basis. We aimed to investigate, with a cross-sectional study, the prevalence of disease categories, treatment methods, and disease status in patients from across different geographical areas and from countries with diverse wealth status.

Methods: In this multinational, cross-sectional, observational cohort study, we asked international paediatric rheumatologists from specialised centres to enrol children with a diagnosis of juvenile idiopathic arthritis, according to International League of Associations for Rheumatology criteria, who were seen consecutively for a period of 6 months. Read More

Medicine (Baltimore) 2019 Mar;98(9):e14668

Department of Ophthalmology & Visual Science, Tokyo Medical and Dental University Graduate School of Medicine.

Noninfectious uveitis (NIU), which pathogenesis is often autoimmune nature, occurs as a symptom of systemic syndromes or only in the eye. The standard treatment of NIU is local, topical, and oral administration of corticosteroids (CS) in combination with immunomodulatory therapy (IMT). However, additional therapeutic strategies involving topical and systemic administration of CS or others to treat relapse or exacerbation of ocular inflammation in NIU which present as various ocular manifestations have not been established. Read More

J Clin Pharm Ther 2019 Jun 27;44(3):482-485. Epub 2019 Feb 27.

Department of Human Pathology in Adulthood and Childhood "G. Barresi", University of Messina, Messina, Italy.

What Is Known And The Objective: Low-grade evidence supports the use of newer biologics for otherwise refractory juvenile idiopathic arthritis (JIA)-associated uveitis, such as tocilizumab.

Case Summary: This report details the cases of two adolescents whose severe JIA-associated uveitis was unresponsive to the first-line therapeutic approach. Tocilizumab therapy led to the remission of uveitis after a mean time of 3 weeks, and methotrexate was safely discontinued 1. Read More

Ophthalmology 2019 Mar;126(3):e22-e24

Save Sight Institute, The University of Sydney, Sydney, Australia.

Ophthalmology 2019 Mar;126(3):425-427

Seattle, Washington. Electronic address:

Am J Ophthalmol 2019 Apr 17;200:85-94. Epub 2019 Jan 17.

Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Universidad de Cantabria, Santander, Spain. Electronic address:

Purpose: Cystoid macular edema (CME) is a leading cause of blindness. This study assessed the efficacy and safety of tocilizumab (TCZ) in refractory CME.

Design: Retrospective case series. Read More

Semin Arthritis Rheum 2018 Dec 4. Epub 2018 Dec 4.

The Society for Paediatric Rheumatology (GKJR), Germany.

Background: Uveitis in juvenile idiopathic arthritis (JIAU) is frequently associated with the development of complications and visual loss. Topical corticosteroids are the first line therapy, and disease modifying anti-rheumatic drugs (DMARDs) are commonly used. However, treatment has not been standardized. Read More

Rheumatology (Oxford) 2018 Dec 26. Epub 2018 Dec 26.

German Rheumatism Research Center, a Leibniz Institute, Berlin.

Objective: To define predictors for the 2-year outcome in terms of achieving inactivity, subsequent uveitis reactivation and occurrence of uveitis-related complications of JIA-associated uveitis.

Methods: Demographic and clinical parameters and serum samples of JIA-associated uveitis patients enrolled in ICON at ⩽1 year of JIA diagnosis were collected at study enrolment, every 3 months during the first year and subsequently every 6 months. Predictors for the 2-year outcome were evaluated by linear mixed models. Read More

Clin Exp Rheumatol 2018 Nov-Dec;36(6 Suppl 115):68-73. Epub 2018 Dec 12.

Research Centre of Systemic Autoinflammatory Diseases and Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Centre, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.

Objectives: To describe the epidemiology of non-infectious uveitis (NIU) in two tertiary referral rheumatology units in Central and Southern Italy.

Methods: Two hundred and seventy-eight consecutive NIU patients (417 eyes) evaluated between January 2016 and January 2017 were enrolled. Collected data were analysed in accordance with the primary anatomic site of inflammation, clinical course, and laterality. Read More

Indian J Ophthalmol 2019 Jan;67(1):165-167

INSERM UMR1163, Laboratory of Neurogenetics and Neuroinflammation, Paris Descartes University, Sorbonne-Paris-Cité, Institut Imagine, Paris, France; Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.

Blau syndrome (BS) is a rare autoinflammatory disorder characterized by the clinical triad of arthritis, uveitis, and dermatitis due to heterozygous gain-of-function mutations in the NOD2 gene. BS can mimic juvenile idiopathic arthritis (JIA)-associated uveitis, rheumatoid arthritis, and ocular tuberculosis. We report a family comprising a mother and her two children, all presenting with uveitis and arthritis. Read More

Indian J Ophthalmol 2019 Jan;67(1):69-74

Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.

Purpose: To assess the safety and efficacy of intraoperative intravitreal dexamethasone implant in patients of juvenile idiopathic arthritis (JIA)-associated uveitis undergoing phacoemulsification with posterior chamber intraocular lens (PCIOL) implantation.

Methods: Retrospectively, data of patients with JIA-associated uveitis undergoing phacoemulsification with PCIOL implantation with intraoperative dexamethasone implant injection were analyzed. Patients with a minimum follow-up of 6 months were included. Read More

Pediatr Rheumatol Online J 2018 Dec 14;16(1):79. Epub 2018 Dec 14.

Department of Rheumatology, Ajou University of medical school, 164 Worldcup-ro, Yeongtong-gu, Suwon, 16499, Republic of Korea.

Tocilizumab, an anti-interleukin-6 (IL-6) agent, is indicated as a treatment for several autoimmune or inflammatory diseases, including rheumatoid arthritis and juvenile idiopathic arthritis (JIA). IL-6 plays roles in both immune system dysregulation and inflammation, and thus efforts to extend the utility of tocilizumab in patients with autoinflammatory conditions are ongoing. Here, we survey the literature on the off-label use of tocilizumab in patients with juvenile-onset rheumatic diseases including juvenile systemic lupus erythematosus (SLE), juvenile dermatomyositis (DM), vasculitis, juvenile scleroderma, and other autoinflammatory diseases. Read More

Arthritis Res Ther 2018 Dec 13;20(1):276. Epub 2018 Dec 13.

German Rheumatism Research Center, a Leibniz Institute, Charitéplatz 1, 10117, Berlin, Germany.

Objective: The objective was to evaluate the 25(OH) vitamin D (25(OH)D) status of patients with juvenile idiopathic arthritis (JIA) and determine whether the 25(OH)D level is associated with disease activity and the course of JIA.

Methods: Patients ≤ 16 years of age with recently diagnosed JIA (< 12 months) were enrolled in the inception cohort of patients with newly diagnosed JIA (ICON), an ongoing prospective observational, controlled multicenter study started in 2010. Clinical and laboratory parameters were ascertained quarterly during the first year and half-yearly thereafter. Read More

Eye (Lond) 2019 Apr 28;33(4):629-639. Epub 2018 Nov 28.

Division of Rheumatology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA.

Aims: Methotrexate (MTX) is standard treatment in pediatric chronic anterior uveitis (CAU). Addition of tumor necrosis factor-α inhibitors (TNFi) is often needed. We describe the timing and risk factors for TNFi use in children with CAU on MTX. Read More

Ophthalmology 2019 Mar 16;126(3):415-424. Epub 2018 Oct 16.

Bristol Medical School, University of Bristol, Bristol, United Kingdom; University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.

Purpose: To investigate the cost effectiveness of adalimumab in combination with methotrexate, compared with methotrexate alone, for the management of uveitis associated with juvenile idiopathic arthritis (JIA).

Design: A cost-utility analysis based on a clinical trial and decision analytic model.

Participants: Children and adolescents 2 to 18 years of age with persistently active uveitis associated with JIA, despite optimized methotrexate treatment for at least 12 weeks. Read More

Ocul Immunol Inflamm 2018 Oct 17:1-11. Epub 2018 Oct 17.

b Department of Ophthalmology, Hadassah Medical Center , The Hebrew University Hadassah Medical School , Jerusalem , Israel.

Purpose: To report the epidemiology, etiology, ocular characteristics, treatment and visual outcome of pediatric uveitis in Israel.

Methods: Retrospective study from two tertiary uveitis centers.

Results: Included were 107 patients (182 eyes), 55% females. Read More

J Ophthalmic Inflamm Infect 2018 Oct 16;8(1):17. Epub 2018 Oct 16.

UCLA Stein Eye Institute and David Geffen School of Medicine at University of California, 100 Stein Plaza, Los Angeles, CA, 90095-7000, USA.

Background: Biomarkers in easily obtained specimens that accurately predict uveitis in children with juvenile idiopathic arthritis (JIA) are needed. Aqueous humor has been studied for biomarkers, but is not routinely available. We evaluated tears from children with chronic anterior uveitis (CAU) for biomarkers reported in aqueous humor. Read More

Arthritis Care Res (Hoboken) 2018 Oct 15. Epub 2018 Oct 15.

Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, Canada.

Objective: Identification of the incidence of Juvenile Idiopathic Arthritis (JIA)-associated uveitis and its risk factors is essential to optimize early detection. Data from the Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh-Out) inception cohort were used to estimate the annual incidence of new-onset uveitis following JIA diagnosis and identify associated risk factors.

Methods: Data were reported every 6 months for 2 years, then yearly to 5 years. Read More

Zhonghua Er Ke Za Zhi 2018 Oct;56(10):786-789

Orthopade 2018 Nov;47(11):910-916

Abteilung für Rheumaorthopädie und Handchirurgie, Zentrum für Rheumatologie, Orthopädie und Schmerztherapie, Klinik Oberammergau, Oberammergau, Deutschland.

The treatment of children and adolescents with juvenile idiopathic arthritis (JIA) has progressed substantially during recent years. Multiple different factors have played a role in this advancement: improved medical treatment due to the introduction of new drugs, structural improvements with provision of units specializing in childhood rheumatology, multidisciplinary treatment concepts, structured educational programs for patients and parents, improved functional treatment including sports therapy, and selective surgical and orthopedic interventions improving functional capacities. Current treatment strategies in JIA are aimed at achieving disease remission, i. Read More

Rheumatol Int 2019 Jan 1;39(1):13-27. Epub 2018 Oct 1.

Department of Pediatrics, Division of Rheumatology, Ankara Training and Research Hospital, University of Health Sciences, Ankara, 06100, Turkey.

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of joints in childhood. Glucocorticoids are being used in JIA treatment effectively for decades. Although systemic glucocorticoid use decreased with the introduction of biologic drugs, intraarticular glucocorticoid injections (IAGI) with nonsteroidal anti-inflammatory drugs and non-biologic disease modifying anti-rheumatic drugs (DMARDs) still remain the primary treatment in JIA, especially in oligoarticular subcategory. Read More

BioDrugs 2018 Oct;32(5):507-510

Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

SB5 (Imraldi) is a biosimilar of the reference anti-TNF monoclonal antibody adalimumab. It is approved for use in the following indications for which reference adalimumab is approved: rheumatoid arthritis (RA), juvenile idiopathic arthritis [polyarticular juvenile idiopathic arthritis (pJIA) and enthesitis-related arthritis (ERA)], axial spondyloarthritis [ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)], psoriatic arthritis (PsA), psoriasis, pediatric plaque psoriasis, hidradenitis suppurativa (HS), Crohn's disease, pediatric Crohn's disease, ulcerative colitis (UC), and non-infectious uveitis. SB5 has similar physicochemical and pharmacodynamic properties to those of reference adalimumab, and the pharmacokinetic similarity of these agents has been shown in healthy volunteers and patients with RA. Read More

Pediatr Qual Saf 2018 May-Jun;3(3):e084. Epub 2018 Jun 13.

Division of Rheumatology, Nationwide Children's Hospital, Columbus, Ohio.

Introduction: Uveitis is a significant complication in patients with juvenile idiopathic arthritis (JIA) and can be asymptomatic until vision loss develops. Published guidelines recommend uveitis screening eye examinations every 3-12 months depending on multiple factors, but no literature evaluates adherence with and barriers to obtaining these screening eye examinations. This study assesses barriers in nonadherent patients to establish key drivers for future interventions. Read More

Eur J Ophthalmol 2018 Sep 12:1120672118799623. Epub 2018 Sep 12.

1 St. Erik Eye Hospital, Stockholm, Sweden.

Purpose: To evaluate the long-term outcome after cataract surgery with primary intraocular lens implantation in children with juvenile idiopathic arthritis-associated uveitis.

Methods: The medical records of all 24 children (34 eyes) with chronic juvenile idiopathic arthritis-associated uveitis who underwent cataract surgery between 1990 and 2013 were reviewed retrospectively. Primary intraocular lens implantation was performed in all patients. Read More

Rom J Ophthalmol 2018 Apr-Jun;62(2):105-113

"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

Purpose: Non-infectious uveitis has been long controlled with the use of corticosteroids with many side effects and poor control in some cases. The purpose of this paper was to assess the different biologic agents (in this case infliximab and adalimumab) and to compare their efficacy in the treatment of uveitis.

Results: Adalimumab has been proven very successful in replacing or aiding corticosteroid therapy in different autoimmune mediated uveitis (Juvenile Idiopathic Arthritis, Rheumatoid arthritis, sarcoidosis) whereas infliximab has been used intravenously and recently intravitreally with very promising results in controlling Behcet's related uveitis. Read More

Mod Rheumatol 2019 Jan 29;29(1):41-59. Epub 2018 Oct 29.

k Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences , Tokyo Medical and Dental University , Tokyo , Japan.

Juvenile idiopathic arthritis (JIA) is the most common disease in pediatric rheumatism. There is no specific symptom or examination finding for JIA, and the diagnosis is made by exclusion and differentiation. Because non-pediatric rheumatologists are sometimes involved in medical care, 'proposal for JIA guidance on diagnosis and treatment for primary care pediatricians and non-pediatric rheumatologists' was first published in 2007. Read More

Pediatr Rheumatol Online J 2018 Aug 6;16(1):51. Epub 2018 Aug 6.

University Hospitals Bristol NHS Foundation Trust, Bristol, UK.

Background: There is a paucity of data on the ocular outcomes in paediatric non-infectious uveitis since the introduction of the biologic agents. The purpose of this study was to outline the clinical characteristics of children with non-infectious uveitis and determine the visual outcomes and ocular complication rates in the modern era.

Methods: Children with non-infectious uveitis from January 2011 to December 2015 were identified. Read More

Reumatologia 2018 30;56(3):149-154. Epub 2018 Jun 30.

Department of Pediatric Rheumatology, Medical University of Łodz, Maria Konopnicka Memorial Teaching Hospital No. 4 in Lodz, Poland.

Objectives: Uveitis and juvenile idiopathic arthritis (JIA) relatively often coexist. Inflammatory changes in the anterior segment of the eye are the most common extra-articular symptom in children with JIA, and JIA is, in turn, the main systemic cause of anterior uveitis in children. The aim of our study was to compare the course of anterior uveitis accompanying JIA and isolated uveitis. Read More

Pediatr Clin North Am 2018 08;65(4):657-674

Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, 1600 7th Avenue South, CPPN G10, Birmingham, AL 35233, USA. Electronic address:

Juvenile idiopathic arthritis (JIA) comprises a group of heterogeneous diseases further divided into various categories based on shared clinical presentation, laboratory markers, and disease prognosis. Extra-articular complications include uveitis and growth abnormalities. Disease course and prognosis vary with respect to each JIA category and subsequently guide respective treatment. Read More

Arch Dis Child 2019 Mar 19;104(3):246-250. Epub 2018 Jul 19.

Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria.

Objectives: Assessing influence of anti-adalimumab (ADA) antibodies (AAA) on serum trough ADA levels and uveitis activity in long-term ADA treatment of juvenile idiopathic arthritis (JIA)-associated uveitis.

Patients And Interventions: This prospective observational study included 20 patients from a single centre treated with ADA for active uveitis refractory to conventional disease-modifying antirheumatic drugs. AAA, serum ADA trough levels and uveitis activity were evaluated at regular intervals up to 6 years. Read More

Pediatr Rheumatol Online J 2018 Jul 11;16(1):46. Epub 2018 Jul 11.

Rheumatology Unit, Anna Meyer Children Hospital and University of Florence, University of Florence, Florence, Italy.

Background: Conventional pharmacological therapies for the treatment of juvenile idiopathic arthritis (JIA) consist of non-biological, disease-modifying antirheumatic drugs, among which methotrexate (MTX) is the most commonly prescribed. However, there is a lack of consensus-based clinical and therapeutic recommendations for the use of MTX in the management of patients with JIA. Therefore, the Methotrexate Advice and RecommendAtions on Juvenile Idiopathic Arthritis (MARAJIA) Expert Meeting was convened to develop evidence-based recommendations for the use of MTX in the treatment of JIA. Read More

Br J Ophthalmol 2018 Jun 15. Epub 2018 Jun 15.

Department of Ophthalmology, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.

Aims: To analyse the clinical features, systemic associations, treatment and visual outcomes of uveitis in children from a referral centre in São Paulo, Brazil.

Methods: Clinical records of patients under 16 years old who attended the Uveitis Service, Hospital das Clinicas, Faculdadede Medicina, Universidade de São PauloFMUSP, between April and September 2017, were reviewed retrospectively. Patients with incomplete medical records, previous ocular trauma, or less than six6 months of follow-up were excluded. Read More

Arthritis Care Res (Hoboken) 2019 Apr;71(4):482-491

Duke University Medical Center, Durham, North Carolina.

Objective: Systemic immunosuppressive treatment of pediatric chronic anterior uveitis (CAU), both juvenile idiopathic arthritis-associated and idiopathic anterior uveitis, varies, making it difficult to identify best treatments. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed consensus treatment plans (CTPs) for CAU for the purpose of reducing practice variability and allowing future comparison of treatments using comparative effectiveness analysis techniques.

Methods: A core group of pediatric rheumatologists, ophthalmologists with uveitis expertise, and a lay advisor comprised the CARRA uveitis workgroup that performed a literature review on pharmacologic treatments, held teleconferences, and developed a case-based survey administered to the CARRA membership to delineate treatment practices. Read More

Arthritis Rheumatol 2018 Oct 23;70(10):1533-1543. Epub 2018 Aug 23.

University College London, National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital, London, UK, and University of Bristol, Bristol Eye Hospital, Bristol, UK.

Uveitis is defined as intraocular inflammation. It is an extraarticular manifestation of many forms of joint disease, which include spondyloarthritis, juvenile idiopathic arthritis, and Behçet's disease. Rheumatologists may be asked to consult on the ophthalmologic care of patients with uveitis in order to identify an associated systemic illness. Read More

Best Pract Res Clin Rheumatol 2017 08 26;31(4):517-534. Epub 2018 Feb 26.

Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol, BS2 8BJ, UK. Electronic address:

Juvenile idiopathic arthritis (JIA) is the commonest rheumatic disease in children and JIA-associated uveitis its most frequent extra-articular manifestation. The uveitis is potentially sight-threatening and thus carries a considerable risk of morbidity with associated reduction in quality of life. The commonest form of uveitis seen in association with JIA is chronic anterior uveitis, which is almost always asymptomatic in the initial stages. Read More